Preliminary evaluation of prostate cancer metastatic risk biomarkers.

@article{Paris2005PreliminaryEO,
  title={Preliminary evaluation of prostate cancer metastatic risk biomarkers.},
  author={Pamela L. Paris and Vivian A. Weinberg and Jeffrey P. Simko and Armann Andaya and Giancarlo Albo and Mark A. Rubin and Peter R. Carroll and Colin Collins},
  journal={The International journal of biological markers},
  year={2005},
  volume={20 3},
  pages={141-5}
}
Prostate cancer patients at high risk of metastasis need to be identified as early as possible since metastasis is invariably fatal. Treatment could be tailored to risk. Recent array comparative genomic hybridization (aCGH) studies of primary and metastatic prostate tumors identified 39 BAC clones capable of detecting genomic signatures of metastasis. We termed these loci the genomic evaluators of metastatic CaP (GEMCaP). Risk assessments were made on a set of men who were managed with radical… CONTINUE READING